Citation Impact
Citing Papers
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
2008
ESUR prostate MR guidelines 2012
2012 Standout
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement
2015 Standout
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
2016
Reporting methods in studies developing prognostic models in cancer: a review
2010
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate
2011
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
2015 Standout
Updated concepts and treatment of carcinoma in situ
1998
Do Prognostic Parameters of Remission versus Relapse after Bacillus Calmette–Guérin (BCG) Immunotherapy Exist? Analysis of a Quarter Century of Literature
2003
Optimal Management of the T1G3 Bladder Cancer
2005
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
2015 Standout
Towards better clinical prediction models: seven steps for development and an ABCD for validation
2014 Standout
Should All Patients with Non–Muscle-Invasive Bladder Cancer Receive Early Intravesical Chemotherapy after Transurethral Resection? The Results of a Prospective Randomised Multicentre Study
2009
T1G3 Bladder Tumours: The Case for Radical Cystectomy
2003
Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors
2009
Current perspectives in muscle invasive bladder cancer
2002
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial
2005
Guidelines on Bladder Cancer
2002
The prevention of overweight and obesity in children and adolescents: a review of interventions and programmes
2006
Immediate Post–Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non–Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review
2013
A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?
2004
Epidemiology of Prostate Cancer
2019 Standout
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
2012
The Value of a Second Transurethral Resection in Evaluating Patients with Bladder Tumours
2003
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer
2002
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder
2012
Inadequacy of Biopsy for Diagnosis of Upper Tract Urothelial Carcinoma: Implications for Conservative Management
2011
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Can patient selection for bladder preservation be based on response to chemotherapy?
2003
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
2015
Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance
2006
Factors Explaining Recurrence in Patients Undergoing Chemoimmunotherapy Regimens for Frequently Recurring Superficial Bladder Carcinoma
2002
Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
2007
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Urothelial Carcinoma of the Prostate
2007
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
2016 Standout
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-guérin–RIVM and mitomycin c in superficial bladder cancer
1998
EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ
2005
Bladder cancer
2016 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
One Immediate Postoperative Instillation of Chemotherapy in Low Risk Ta, T1 Bladder Cancer Patients. Is it Always Safe?
2004
The clinical epidemiology of superficial bladder cancer
1993
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers
2012
Photodynamic therapy and anti-tumour immunity
2006 Standout
Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guérin
2011
Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma
2009
Seguimiento oncológico después de cistectomía radical basado en patrones de recidiva tumoral y sus factores de riesgo
2013
Bacillus Calmette‐Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression
2004
Urothelial carcinoma management in elderly or unfit patients
2016
Maximizing Cure for Muscle-Invasive Bladder Cancer: Integration of Surgery and Chemotherapy
2011
The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials
2008
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
2013 Standout
Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
2013
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
Upper Urinary Tract Transitional Cell Carcinoma: Recurrence Rate after Percutaneous Endoscopic Resection
2006
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder
2005
Epidemiology and Risk Factors of Urothelial Bladder Cancer
2012 Standout
Reporting performance of prognostic models in cancer: a review
2010
Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer
2006
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement
2015 Standout
Bladder cancer: Epidemiology, staging and grading, and diagnosis
2005 Standout
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
2005
5α-Reductase inhibitor treatment of prostatic diseases: background and practical implications
2008
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review
2012
Cystectomy in Patients with High Risk Superficial Bladder Tumors Who Fail Intravesical BCG Therapy:
2005
Treatment Options Available for Bacillus Calmette-Guérin Failure in Non–muscle-invasive Bladder Cancer
2012
Carcinoma of the upper urinary tract
2009
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
2009 Standout
The optimum timing of radical cystectomy for patients with recurrent high‐risk superficial bladder tumour
2004
Risk-adapted strategy for the kidney-sparing management of upper tract tumours
2015
EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
2011
Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature
2012
Is There a Role for FISH in the Management and Surveillance of Patients with Upper Tract Transitional-Cell Carcinoma?
2008
Natural History, Recurrence, and Progression in Superficial Bladder Cancer
2006
A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small Recurrences
2007
A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study
2007
RESTAGING TRANSURETHRAL RESECTION OF HIGH RISK SUPERFICIAL BLADDER CANCER IMPROVES THE INITIAL RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY
2005
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Behavior of Urothelial Carcinoma With Respect to Anatomical Location
2007
Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data
2005 Standout
HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA
2005
Bladder Cancer
2020 Standout
Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update
2007
A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS
2004
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
2007
Follow-up after radical cystectomy based on patterns of tumor recurrence and its risk factors
2013
Upper Urinary Tract Recurrence Following Radical Cystectomy for Bladder Cancer: A Meta-Analysis on 13,185 Patients
2012
Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy
2003 Standout
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update
2012
ASSESSMENT OF VESICOURETERAL REFLUX IN PATIENTS WITH SELF-RETAINING URETERAL STENTS: IMPLICATIONS FOR UPPER URINARY TRACT INSTILLATION
2005
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
CYSTECTOMY FOR BLADDER CANCER: A CONTEMPORARY SERIES
2001
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
UPPER URINARY TRACT TUMORS AFTER PRIMARY SUPERFICIAL BLADDER TUMORS: PROGNOSTIC FACTORS AND RISK GROUPS
2000
Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles
2009
FLUORESCENCE ENDOSCOPY WITH 5-AMINOLEVULINIC ACID REDUCES EARLY RECURRENCE RATE IN SUPERFICIAL BLADDER CANCER
2001
Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup
2007
Segmental Ureterectomy Can Safely be Performed in Patients With Transitional Cell Carcinoma of the Ureter
2010
Feasibility of Radical Transurethral Resection as Monotherapy for Selected Patients With Muscle Invasive Bladder Cancer
2010
Neoadjuvant Chemotherapy for Transitional Cell Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
2004
Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence Cystoscopy
2004
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
2015 Standout
MULTIVARIATE ANALYSIS OF CLINICAL PARAMETERS OF SYNCHRONOUS PRIMARY SUPERFICIAL BLADDER CANCER AND UPPER URINARY TRACT TUMOR
2005
Transurethral Resection of Muscle-Invasive Bladder Cancer: 10-Year Outcome
2001
A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group
2011
Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma
2003
Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials
2002 Standout
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma
2016
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence
2018
Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer
2016
Works of E. Solsona being referenced
Carcinoma in situ Associated with Superficial Bladder Tumor
1991
Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): Its impact on management
1997
FEASIBILITY OF TRANSURETHRAL RESECTION FOR MUSCLE INFILTRATING CARCINOMA OF THE BLADDER: LONG-TERM FOLLOWUP OF A PROSPECTIVE STUDY
1998
Recurrence of Superficial Bladder Tumors in Prostatic Urethra
1991
Improving the Safety ofBCG Immunotherapy by DoseReduction
1995
Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Specimens
2005
THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCER
2000
Late Oncological Occurrences Following Radical Cystectomy in Patients with Bladder Cancer
2003
The clinical implications of the Prostate Cancer Prevention Trial
2003
Conservative Elective Treatment of Upper Urinary Tract Tumors: A Multivariate Analysis of Prognostic Factors For Recurrence and Progression
2003
Random trial comparing intravesical chemo-induction with MMC to BCG vs. intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Efficacy evaluation of CUETO Trial No 93008
2002
RISK GROUPS IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: STATISTICAL AND CLINICAL MODEL IMPROVING HOMOGENEITY
2005
Conservative Elective Treatment of Upper Urinary Tract Tumors: A Multivariate Analysis of Prognostic Factors For Recurrence and Progression
2003
1155 A phase III trial of neoadjuvant chemotherapy (NCT) in patients (PTS) with invasive bladder cancer (IBC). Preliminary results: NCT improves pathological complete response rate
1995
486 Random trial comparing intravesical chemo-induction with MMC to BCG vs. intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Final report of efficacy evaluation of cueto trial N°93009
2004
Feasibility of Transurethral Resection for Muscle-Infiltrating Carcinoma of the Bladder: Prospective Study
1992
EFFECTIVENESS OF A SINGLE IMMEDIATE MITOMYCIN C INSTILLATION IN PATIENTS WITH LOW RISK SUPERFICIAL BLADDER CANCER: SHORT AND LONG-TERM FOLLOWUP
1999
Clinical Panurothelial Disease in Patients with Superficial Bladder Tumors: Therapeutic Implications
2002
The Prostate Involvement As Prognostic Factor in Patients with Superficial Bladder Tumors
1995
Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.
2010
Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression.
2003
THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCER
2000
Extravesical Involvement in Patients with Bladder Carcinoma In Situ: Biological and Therapy Implications
1996